X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 71.69 CNY -3.54% Market Closed
Market Cap: 29.2B CNY
Have any thoughts about
Xiamen Amoytop Biotech Co Ltd?
Write Note

Xiamen Amoytop Biotech Co Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Xiamen Amoytop Biotech Co Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Other Long-Term Assets
ÂĄ84m
CAGR 3-Years
45%
CAGR 5-Years
25%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Other Long-Term Assets
ÂĄ304.3m
CAGR 3-Years
-29%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Other Long-Term Assets
ÂĄ405.6m
CAGR 3-Years
39%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Other Long-Term Assets
ÂĄ132.9m
CAGR 3-Years
-37%
CAGR 5-Years
-12%
CAGR 10-Years
9%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Other Long-Term Assets
ÂĄ1.2B
CAGR 3-Years
21%
CAGR 5-Years
33%
CAGR 10-Years
46%
Imeik Technology Development Co Ltd
SZSE:300896
Other Long-Term Assets
ÂĄ81.1m
CAGR 3-Years
29%
CAGR 5-Years
53%
CAGR 10-Years
N/A
No Stocks Found

Xiamen Amoytop Biotech Co Ltd
Glance View

Market Cap
29.2B CNY
Industry
Biotechnology

Xiamen Amoytop Biotech Co. Ltd. engages in the research and development of genetic engineering technology. The company is headquartered in Xiamen, Fujian and currently employs 1,261 full-time employees. The company went IPO on 2020-01-17. The firm's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
86.96 CNY
Undervaluation 18%
Intrinsic Value
Price
X

See Also

What is Xiamen Amoytop Biotech Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
84m CNY

Based on the financial report for Dec 31, 2023, Xiamen Amoytop Biotech Co Ltd's Other Long-Term Assets amounts to 84m CNY.

What is Xiamen Amoytop Biotech Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
25%

Over the last year, the Other Long-Term Assets growth was 31%. The average annual Other Long-Term Assets growth rates for Xiamen Amoytop Biotech Co Ltd have been 45% over the past three years , 25% over the past five years .

Back to Top